Delving into the Latest Updates on ZM-02 with Synapse

Overview

Basic Info

Drug Type

AAV based gene therapy

Synonyms

Recombinant human adeno-associated virus serotype 2 containing PsCatCh2.0 gene (Zhongmou), rAAV-PsCatCh2.0 (Zhongmou)

+ [1]

Target-

Mechanism-

Therapeutic Areas

Congenital DisordersEye DiseasesOther Diseases

Active Indication

Retinitis PigmentosaAge Related Macular Degeneration

Inactive Indication-

Originator Organization

Zhongmou Therapeutics (Wuhan) Co., Ltd.

Active Organization

Zhongmou Therapeutics (Wuhan) Co., Ltd.

Inactive Organization-

Drug Highest PhaseEarly Phase 1

First Approval Date-

RegulationOrphan Drug (US)

Login to view timeline

κ-Carrageenases exhibit apparent distinctions in gene sequence, molecular weight, enzyme properties, and posttranslational processes. In this study, a new κ-carrageenase gene named cgkZ was cloned from the marine bacterium Zobellia sp. ZM-2. The gene comprised an open reading frame of 1,638 bp and encoded 545 amino acids. The natural signal peptide of κ-carrageenase was used successfully for the secretory production of the recombinant enzyme in Escherichia coli. A posttranslational process that removes an amino acid sequence of about 20 kDa from the C-terminal end of κ-carrageenase was first discovered in E. coli. An increase in enzyme activity by 167.3% in the presence of 5 mM DTT was discovered, and Na(+) at a certain concentration range was positively correlated with enzyme activity. The κ-carrageenase production of E. coli was 9.0 times higher than that of ZM-2. These results indicate the potential use of the enzyme in the biotechnological industry.

100 Deals associated with ZM-02

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Retinitis Pigmentosa	Phase 1	CN	Zhongmou Therapeutics (Wuhan) Co., Ltd.	25 Feb 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EURETINA2024	Not Applicable	Retinitis Pigmentosa	-	ZM-02 high dose	aboeouupfq(xnmmzaxsis) = one subject experienced temporary, controllable anterior inflammation bpburegkuh (uvkcywgiev )	-	19 Sep 2024
				ZM-02 low dose